Guillaume Taylor

Banque Lombard Odier & Cie SA (Investment Management) (Lombard Odier-IM) is the investment management division of Banque Lombard Odier & Cie, a subsidiary of Compagnie Lombard Odier SCmA in Switzerland. The firm was founded in 2002 when Lombard Odier & Cie and Darier Hentsch & Cie. merged. They are headquartered in Geneva with branches and representative offices throughout Switzerland, Europe, the Americas, Asia Pacific and the Middle East. Lombard Odier-IM provides private banking and asset management services to institutions, family-owned businesses and high-net worth individuals. They also provide a range of support services for independent intermediaries.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

BridgeCo, a networked entertainment pioneer, offers the world’s most comprehensive, cost-effective and highly integrated processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the multi-billion dollar global market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland.

SIFEM AG (SIFEM) is the Swiss Development Finance Institution. It provides long-term finance to private equity funds and financial institutions in emerging markets. SIFEM's primary focus is on institutions investing in the small and medium enterprise sector. On a selective basis, SIFEM also invests in microfinance.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Ethos Services SA (Ethos Services) is the investment management subsidiary of Ethos, Fondation suisse pour un développement durable, created in Geneva, Switzerland in 1997 by two pension funds and backed by institutional investors. Ethos Services provides all investment activities and advising for the Ethos Foundation. They are a leading socially responsible investment firm which provides fund advising and manages discretionary mandates. They provide the opportunity to invest with criteria of sustainable development, actively exercise the voting rights of shareholders and engage in dialogue with companies.

BRUGG GROUP AG engages in the production, sale, and distribution of cables and ropes. Its products include power and telecommunication cables and accessories, special cables for industry and security, process control systems for water treatment and energy management, pipe systems for the transport and distribution of liquids, as well as ropes for aerial ropeways, elevators, and cranes rope protection systems against natural hazards. The company was founded by Gottlieb Suhner in 1896 and is headquartered in Brugg, Switzerland.

Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA.

Aravis Venture II LP invests in biotechnological start-ups with growth potential.

Foncière Terre de Liens SCA operates as an investment company. Its activities include acquisition and leasing of agricultural land. The company was founded on December 11, 2006 and is headquartered in Crest, France.

Inrate AG is an independent sustainability rating agency headquartered in Zurich, Switzerland. The firm was founded in 1990 and is owned by Infras AG, the NEST Foundation and by members of the Board of Directors. They support clients (banks, insurances, pension funds, NGOs and foundations) with in depth knowledge of sustainability research helping them develop, and successfully implement, innovative sustainability solutions. The research universe of Inrate currently comprises of listed companies, unlisted companies with listed bonds, sovereign states, supranational institutions and real estate. Geographically, the universe comprises large and medium-sized Swiss equities and all bonds listed in Switzerland. They evaluate all companies in the MSCI World and MSCI Emerging Markets worldwide. Inrate is a signatory to the United Nations Principles for Responsible Investment (UNPRI).

Fatzer AG Drahtseilfabrik engages in the development, production, and sale of wire ropes, wire rope products and accessories, as well as rockfall, avalanche, and erosion control systems. The company was founded on April 3, 1933 and is headquartered in Romanshorn, Switzerland.

Covalence SA is an independent Swiss investment research firm which was co-founded by Antoine Mach and Marc Rochat in 2001. Headquartered in Carouge, the firm delivers data and research to corporates, academics and non-profits relying on its EthicalQuote reputation index. Their services includes ESG ratings, ESG news data, portfolio advisory, and impact stories, and support sustainable and responsible investment, ESG integration and impact investing strategies. Covalence is a socially responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI).

Symbiotics Asset Management SA (Investment Management) (Symbiotics-IM) is the asset management division of Symbiotics Asset Management SA, a market access platform for impact investing which is headquartered in Geneva, Switzerland. The firm was founded by Roland Dominicé in 2004 as Symbiotics SA. Symbiotics-IM creates tailored impact portfolios for institutional investors, such as pension funds, insurance companies or development finance institutions. They also work with global banks and asset managers to create private debt impact funds for their institutional, corporate and high net worth individual (HNWI) clientele.

SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands.

Impact Finance Management SA (Impact Finance) is an independent asset management firm headquartered in Les Acacias, Switzerland. The firm was founded by Cedric Lombard in 2010. Impact Finance provides investment solution to various investors. Their flagship is the Impact Finance Fund, focused on investing in agri- & food businesses.

Swiss Sustainable Finance (SSF) is a leading centre for sustainable finance based in Zurich, Switzerland. The Swiss company offers free e-learning modules on sustainable finance in English, German, and French, with certificates awarded upon completion. SSF collaborates with major Swiss financial services associations and foreign organizations on sustainable finance topics. The private company operates four platforms with focus groups working on specific topics. SSF has an elected Board and a President who steer strategic priorities, while the Secretariat implements the strategy and related activities, maintains regular communication with members and the broader public, and serves as a point of call for members. SSF also creates videos on topics around sustainable finance and hosts an annual event.

AD Education SAS provides digital platform solutions for academic institutions. It offers courses in fields of design, animation, video games, heritage, gemology, perfume, communication, and digital. The company was founded on January 8, 2009 and is headquartered in Paris, France.

Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland.

DyCare is a Spanish company that specializes in digital rehabilitation. The company is based in Barcelona, Spain. The company creates ultra-personalized exercises and monitor patients in a simple and effective way. The company's technology allows patients to perform therapeutic exercises using only their mobile phone or tablet camera, assisted by artificial intelligence. The company was founded by Silvia Raga and Ricardo Jauregui, who have been the CEOs since incorporation.

Soundtrack your brand Sweden AB operates an online platform that enables users to stream and download unlimited music. Its platform includes spotify business which provides small businesses with a powerful musical toolbox and legal access to Spotify's music universe. The company also offers Spotify for Enterprise accounts to express brands through the music of Spotify. Soundtrack Your Brand Sweden was founded by Anders Ola Sars and Andreas Lars Liffgarden in 2013 and is headquartered in Stockholm, Sweden.